What were we asked to look at?

We were asked to provide advice on the clinical and cost effectiveness of transcatheter aortic valve implantation (TAVI) for the treatment of patients with severe symptomatic aortic stenosis who are at low to intermediate surgical risk, compared with surgical aortic valve replacement (SAVR).

Why is this important?

Aortic stenosis is the most common primary valve disease in Europe and North America, usually occurring as a result of age-related degeneration and calcification of the aortic valve. This work will inform service planning by NHSScotland's Strategic Planning Board.

Referred by

National Planning Team, Strategic Planning Board.